Eligible women in S’pore to get subsidised access to broader HPV9 vaccine from 2027

Those who started their vaccination series with HPV2 or HPV4, and are pending further doses, may complete it by receiving the HPV9 vaccine.

Published Oct 02, 2026, 05:30 PM

Updated Oct 02, 2026, 05:30 PM

SINGAPORE - Eligible women looking to guard against cervical cancer will be able to get the Gardasil 9 vaccine, which offers broader protection against the human papillomavirus (HPV), at a subsidised rate in Singapore from Jan 1, 2027 .

Secondary 1 and 2 girls will also be given the vaccine, also known as HPV9, in schools in place of the HPV2 vaccine from the same date.

In a joint statement on Oct 2, the Ministry of Health, Health Promotion Board (HPB) and the Communicable Diseases Agency announced the addition of Gardasil 9 to Singapore’s national immunisation schedules and subsidised vaccine list.

With this, eligible Singaporean adults will be able to receive means-tested subsidies of up to 75 % for the HPV9 vaccine, while permanent residents can receive subsidies at polyclinics .

Meanwhile, eligible Singaporean children can receive full subsidies at CHAS GP clinics and polyclinics.

HPV vaccination is recommended for females aged nine to 26.

HPV9, which will be added to the National Childhood Immunisation Schedule (NCIS) and National Adult Immunisation Schedule (NAIS), covers HPV types responsible for up to 90 % of all cervical cancers.

HPV2, which is also known as Cervarix and protects against up to 70% of all cervical cancers, will remain on both schedules as an alternative option, the statement said.

Meanwhile, HPV4, previously known as Gardasil, is no longer available in Singapore and has been removed from the national schedules.

The agencies said the Expert Committee on Immunisation (ECI) has updated its HPV vaccination recommendations under the NCIS and NAIS:

Ages nine to 14: Two doses are recommended for girls receiving their first dose of either HPV2 or HPV9.

Ages 15 to 26: Three doses are recommended for those receiving their first dose.

Over 26: If HPV vaccination is initiated but not completed by age 26, the remaining doses may be completed after this age, as early as possible, but up to age 45.

Unvaccinated females may start or complete their vaccination series with either the HPV2 or HPV9 vaccine, the statement said.

Meanwhile, those who have started with HPV2 or HPV4, and are pending further doses, may complete their vaccination series by receiving the HPV9 vaccine.

“Studies have shown that such mixed HPV vaccination schedules are safe and provide protection against the HPV strains covered by both vaccines,” the statement said, adding that those who have completed their vaccination schedule do not need additional doses.

Changes to the national school-based HPV vaccination programme

In the statement, the agencies also said the HPV9 vaccine will replace HPV2 under HPB’s school-based immunisation programme.

The vaccination is provided to Secondary 1 and 2 female students at no charge.

Students who have received the HPV2 vaccine as their first dose in 2026, and have not yet completed the series, will be scheduled to receive the HPV9 vaccine as their second dose in 2027.

Female students who have already completed their HPV vaccination series are not eligible for further HPV9 doses, in line with the ECI’s recommendations.

Using MediSave for the HPV9 vaccine

Meanwhile, eligible groups under the NCIS and NAIS will also be able to use up to $700 of their MediSave Chronic and Preventive Care limits for the HPV9 vaccine.

This limit increases to $1,000 for patients who have been treated for at least two Chronic Disease Management Programme (CDMP) conditions, or one CDMP condition with complications, within a calendar year.

Those who have completed the recommended doses will not be able to utilise the vaccination subsidies or MediSave for additional doses of HPV9.

Eligible individuals can book HPV vaccination appointments at participating CHAS GP clinics through https://vaccine.gov.sg or at polyclinics.

Those under Healthier SG are encouraged to book their appointments at their enrolled clinic.

那些已经开始接种 HPV2 或 HPV4 疫苗，并且还在等待后续剂次的人，可以通过接种 HPV9 疫苗来完成疫苗接种。

发布于2026年10月2日下午5:30

更新于2026年10月2日下午5:30

新加坡——从 2027 年 1 月 1 日起，符合条件的女性可以享受补贴价格接种 Gardasil 9 疫苗，以预防宫颈癌。该疫苗可更广泛地预防人乳头瘤病毒 (HPV)。

从同一天起，中学一年级和二年级的女生也将在学校接种HPV9疫苗，以取代HPV2疫苗。

10月2日，卫生部、健康促进局（HPB）和传染病局发表联合声明，宣布将加卫苗9疫苗纳入新加坡国家免疫计划和补贴疫苗清单。

由此，符合条件的新加坡成年人将能够获得高达 75% 的 HPV9 疫苗补贴（需进行经济状况调查），而永久居民可以在综合诊所获得补贴。

与此同时，符合条件的新加坡儿童可在 CHAS 全科诊所和综合诊所获得全额补贴。

建议9至26岁的女性接种HPV疫苗。

HPV9 将被纳入国家儿童免疫计划 (NCIS) 和国家成人免疫计划 (NAIS)，它涵盖了导致高达 90% 宫颈癌的 HPV 类型。

声明称，HPV2（也称为 Cervarix，可预防高达 70% 的宫颈癌）将继续作为替代方案保留在两个接种计划中。

与此同时，HPV4疫苗（以前称为加卫苗）在新加坡已不再提供，并已从国家疫苗接种计划中移除。

这些机构表示，免疫专家委员会（ECI）已根据国家免疫计划（NCIS）和国家免疫计划（NAIS）更新了其HPV疫苗接种建议：

9 至 14 岁：建议女孩在首次接种 HPV2 或 HPV9 疫苗时接种两剂。

15 至 26 岁：建议首次接种疫苗者接种三剂。

26 岁以上：如果 26 岁开始接种 HPV 疫苗但未完成，则可在 26 岁之后尽早完成剩余的剂量，但最晚可至 45 岁。

声明称，未接种疫苗的女性可以开始或完成 HPV2 或 HPV9 疫苗的接种程序。

同时，那些已经开始接种 HPV2 或 HPV4 疫苗，并且正在等待后续剂次的人，可以通过接种 HPV9 疫苗来完成他们的疫苗接种系列。

声明称：“研究表明，这种混合HPV疫苗接种方案是安全的，可以预防两种疫苗所涵盖的HPV病毒株。”声明还补充说，已经完成接种方案的人不需要额外接种。

国家学校HPV疫苗接种计划的变更

声明中，相关机构还表示，HPV9疫苗将取代HPV2疫苗，纳入HPB的学校免疫计划。

中一、中二女生可免费接种疫苗。

2026 年接种了 HPV2 疫苗作为第一剂，但尚未完成整个疗程的学生，将被安排在 2027 年接种 HPV9 疫苗作为第二剂。

根据印度疫苗接种委员会 (ECI) 的建议，已完成 HPV 疫苗接种系列的女学生不符合接种 HPV9 疫苗的条件。

使用 MediSave 支付 HPV9 疫苗费用

同时，符合 NCIS 和 NAIS 资格的群体也可以使用其 MediSave 慢性病和预防保健限额中的 700 美元来接种 HPV9 疫苗。

对于在一个日历年内接受过至少两种慢性疾病管理计划 (CDMP) 疾病治疗的患者，或者接受过一种伴有并发症的 CDMP 疾病治疗的患者，该限额将提高至 1,000 美元。

已完成推荐剂量接种的人将无法使用疫苗补贴或保健储蓄账户（MediSave）接种额外的 HPV9 疫苗。

符合资格的人士可通过 https://vaccine.gov.sg 或综合诊所预约在参与 CHAS GP 计划的诊所接种 HPV 疫苗。

参与“健康新加坡”计划的人士，建议在其注册诊所预约就诊。